Fig. 4

Drug response pattern characteristic of NK cells. a Drugs specific to normal NK cells compared to other hematopoietic cells. Scatter plot comparing median DSS of normal primary NK cells stimulated with 2.5 ng/mL IL-2 (n = 3) to median DSS of unstimulated normal bone marrow mononuclear cells (BM MNC, n = 3). b–e Comparison of drug responses of NK cells (normal IL-2-stimulated NKs, normal K562-aAPC-activated NKs and NK cell lines) and normal BM MNC to ruxolitinib (b), navitoclax (c), venetoclax (d) and dexamethasone (e). Bar height indicates mean DSS and error bars indicate standard deviation. P values were calculated using Welch’s t-test. f Inhibition of IL-2 signaling by JAK, HSP90 and NAE inhibitors. Scatter plot comparing DSS of resting (n = 1) and IL-2-stimulated normal primary NK cells (n = 1). g Ruxolitinib dose–response curves of different PBMC populations in the presence of 2.5 ng/mL IL-2. Shown are representative results from one out of two experiments. Dots indicate mean and error bars the range of three replicate wells. h JAK inhibitor dose–response curves of the cell lines DERL-7 (NK-cell characteristics) and DERL-2 (T-cell characteristics) established in parallel from the same patient with γδ lymphoma. Both cell lines were cultured in 2.5 ng/mL IL-2. Dots indicate mean and error bars the range of two independent experiments